COMPARATIVE STUDY OF THE EFFICACY OF COMBINED SOFOSBUVER RIBAVIRIN IN TREATMENT NAIVE VERSUS EXPERIENCED EGYPTIAN PATIENTS WITH CHRONIC HEPATITIS C.
- Internal medicine department,Faculty of medicine, Banha University ,Qalyubia, Egypt.
- Abstract
- Cite This Article as
- Corresponding Author
and safety of the oral nucleotide polymerase inhibitor sofosbuvir in combination with ribavirin in Egyptian patients, chronically infected with genotype 4 hepatitis C virus (HCV). Methods:Treatment-naive and previously treated patients with genotype 4 HCV were randomly allocated in a 1:1 ratio to receive sofosbuvir 400 mg and weight-based ribavirin, for 24 weeks. The primary efficacy endpoint was the proportion of patients with sustained virologic response (HCV RNA <25 IU/ml) 12 weeks after cessation of therapy (SVR12). Results: treatment-naive and previously treated patients were enrolled and treated for 24 weeks SVR12 was achieved by 68% of patients in the 24-week group. The most common adverse events were headache, insomnia, and fatigue. No patient discontinued treatment due to an adverse event. Conclusions:The findings from the present study suggest that 24 weeks of sofosbuvir plus ribavirin is an efficacious and well tolerated treatment in patients with HCV genotype 4 infection.
[Ayman El-Badawy, Mohamed Yehia Seddek, Mohamed Shawky El-sayed and Azez Mohammed Bedeer. (2016); COMPARATIVE STUDY OF THE EFFICACY OF COMBINED SOFOSBUVER RIBAVIRIN IN TREATMENT NAIVE VERSUS EXPERIENCED EGYPTIAN PATIENTS WITH CHRONIC HEPATITIS C. Int. J. of Adv. Res. 4 (Nov). 1081-1087] (ISSN 2320-5407). www.journalijar.com